Neuroleptic malignant syndrome induced by low dose aripiprazole in first episode psychosis: Commentary

Journal of Psychiatric Practice

Volumn 13, Issue 2, 2007, Pages 118-119

  Gorman, Jack M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; BENZATROPINE; LORAZEPAM;

ASSISTED VENTILATION; CREATINE KINASE BLOOD LEVEL; DRUG MECHANISM; HUMAN; INTENSIVE CARE UNIT; NEUROLEPTIC MALIGNANT SYNDROME; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PSYCHOSIS; SCHIZOPHRENIA; ADULT; ARTICLE; BRADYKINESIA; CASE REPORT; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSPITALIZATION; MUSCLE RIGIDITY; NECK PAIN; NEUROLOGIC EXAMINATION; TREATMENT OUTCOME;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC EXAMINATION; PIPERAZINES; PSYCHOTIC DISORDERS; QUINOLONES;

EID: 34247169934     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000265770.17871.01     Document Type: Note

References (15)

1. Ananth J, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004;65:464-70.
2. Borovicka MC, Bond LC, Gaughan KM. Ziprasidone and lithium induced neuroleptic malignant syndrome. Ann Pharmacotherapy 2006;40:139-42.
3. Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: Review and analysis of 115 cases. Biol Psychiatry 1987;22:1004-20.
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington, DC: American Psychiatric Association; 2000.
5. Grunder G, Kungel M, Ebrecht M, et al. Aripiprazole: Pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry 2006;39 (suppl 1):S21-5.
6. Mann SC, Caroff SN, Fricchione G, et al. Central dopamine hypoactivity and the pathogenesis of neuroleptic malignant syndrome. Psychiatr Ann 2000;30:363-74.
7. Aripiprazole package insert. In: Physicians' Desk Reference, 60th Edition. Montvale, NJ: Thomson PDR; 2006:2472-8.
8. Duggal HS, Kithas J. Possible neuroleptic malignant syndrome with aripiprazole and fluoxetine. Am J Psychiatry 2005;162:397-8.
9. Spalding S, Alessi NE, Radwan K. Aripiprazole and atypical neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry 2004;43:1457-8.
10. Chakraborty N, Johnston T. Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol. 2004;19:351-3.
11. Srephichit S, Sanchez R, Bourgeois JA. Neuroleptic malignant syndrome and aripiprazole in an antipsychotic-naïve patient. J Clin Psychopharmacol 2006;26:94-5.
12. Primeau F, Fontaine R, Chouinard G. Poorly controlled EPS: Risk factors for NMS. Can J Psychiatry 1987;32:328-9.
13. Skarpathiotakis M, Westreich N. NMS after clozapine initiation. J Am Acad Child Adolesc Psychiatry 2005;44:1101-2.
14. Duggal HS. Clozapine-induced neuroleptic malignant syndrome and subdural hematoma. J Neuropsychiatry Clin Neurosci 2004;16:118-9.
15. Susman VL. Clinical management of neuroleptic malignant syndrome. Psychiatry Q 2001;72:325-36.